BTK-IN-17
BTK-IN-17 (compound 36R) is a selective and orally activeBTK inhibitor with an IC50 value of 13.7 nM. BTK-IN-17 decreases the expression of p-BTKY223 and p-PLCγ2Y1217. BTK-IN-17 shows anti-inflammatory effects[1].
Product Specifications
UNSPSC
12352005
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/btk-in-17.html
Solubility
10 mM in DMSO
Smiles
C=CC(N1CC[C@H](C1)N2N=C(C3=CNC4=NC=NC2=C34)NC5=CC=C(C=C5)OC6=CC=CC=C6)=O
Molecular Formula
C26H23N7O2
Molecular Weight
465.51
References & Citations
[1]Fang X, et al. Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis. Eur J Med Chem. 2022 Nov 25;246:114940.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GM-300-15 1 mL
Colloidal Gold Conjugated Sheep Affinity Purified Antibody to Mouse IgG1, 15nm
Sign In for Pricing
View Details 
